Form 4: LMAT Director O'Connor Acquires Shares via Vesting

Lemaitre Vascular Director John James O'Connor acquired 477 shares of common stock through the settlement of a performance share unit award and dividend equivalent rights.

Summary

• John James O'Connor, a Director at Lemaitre Vascular Inc. (LMAT), acquired 476 shares of common stock on February 26, 2026.
• These shares were acquired upon the settlement of a Performance Share Unit (PSU) award granted on December 6, 2024.
• One-third of the PSU award vested upon the determination of satisfaction of the performance condition on February 26, 2026.
• An additional 1 share of common stock was acquired on February 26, 2026, representing the release of dividend equivalent rights.
• Following these transactions, O'Connor beneficially owns 62,827 shares of Lemaitre Vascular Inc. common stock.
• The remaining balance of the PSU award will vest in equal annual installments on the grant date anniversary over the next two years.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it represents an increase in a director's beneficial ownership, aligning their interests with shareholders, even though it's a pre-planned vesting event rather than an open-market purchase.

Positives

• The acquisition of shares increases Director O'Connor's beneficial ownership, further aligning his interests with those of shareholders.
• The vesting of the Performance Share Unit award indicates that performance conditions, as set at the grant date, have been met.

Negatives

• The acquisition was a result of a pre-planned vesting event rather than a discretionary open-market purchase, which typically signals stronger conviction.

Future Outlook

The remaining balance of the Performance Share Unit (PSU) award, granted on December 6, 2024, will vest in equal annual installments on the grant date anniversary over the next two years.

Industry Context

StockSavvy.ai notes that insider acquisitions, even through pre-planned vesting, generally signal continued confidence in the company's long-term prospects and align management's interests with shareholders. This is a common mechanism for executive compensation in the medical device industry.

Stakeholder Impact

• Shareholders: Increased director ownership can be viewed positively as it aligns management's incentives with shareholder value creation.

Next Steps

• The remaining two-thirds of the Performance Share Unit (PSU) award will vest in equal annual installments on the grant date anniversary over the next two years.

Key Dates

Recommendation

The transaction represents the routine vesting of a previously granted performance share unit award and associated dividend equivalent rights, rather than a discretionary open-market purchase or sale. While it increases the director's beneficial ownership, it does not provide new information to warrant a change in investment recommendation.

Keywords

Lemaitre Vascular, LMAT, Insider Transaction, Form 4, Director Stock Acquisition, Performance Share Unit, Dividend Equivalent Rights, Equity Compensation